ExodusPoint Capital Management’s Monte Rosa Therapeutics GLUE Stock Holding History
Bought
Maintained
Sold
Other funds holding GLUE
ExodusPoint Capital Management's GLUE Position: Q3 2026 in Review
ExodusPoint Capital Management sold out of Monte Rosa Therapeutics (GLUE) in Q3 2026, closing a stake of 121,121 shares — an estimated $2.93M sold.
ExodusPoint Capital Management first reported a position in GLUE in Q1 2023 and held it in 10 quarters. The position peaked at $4.59M in Q2 2023. 141 funds tracked by Wall St. Rank hold GLUE as of Q3 2026.
- ExodusPoint Capital Management reported no remaining Monte Rosa Therapeutics position as of Q3 2026 after selling out during the quarter.
- ExodusPoint Capital Management sold 121,121 Monte Rosa Therapeutics shares in Q3 2026, an estimated $2.93M.
- ExodusPoint Capital Management first reported a position in Monte Rosa Therapeutics in Q1 2023 and held it in 10 quarters.
- ExodusPoint Capital Management's Monte Rosa Therapeutics position peaked at $4.59M in Q2 2023.
- 141 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q3 2026.
Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.